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Solid tumors are likely derived from the co-
evolution of neoplastic cells, stromal com-
ponents, vasculature, and immune cells (1).
As tumors evolve and progress, an array
of molecular changes accumulate giving
rise to multiple cell subpopulations, each
with the ability to divide and mutate fur-
ther. In addition, neoplastic cell popula-
tions are able to modulate the behavior
of other types of cells in their microen-
vironment, converting their intrinsic anti-
tumoral into pro-tumoral activity (2, 3).
Therefore, a malignant tumor is composed
not only of neoplastic cells that are het-
erogeneous in terms of genetic and phe-
notypic features, but also by different pro-
tumoral cells and a particular extracellular
matrix that supports cancer evolution and
progression.
Tumor heterogeneity has been recog-
nized as one of the main factors for can-
cer therapy failure, and has just started
to be dissected using next-generation
sequencing (NGS) approaches (4). While
whole genome sequencing, and particu-
larly, exome sequencing have provided the
molecular basis for several complex traits,
RNA and bisulfite sequencing have been
important to disclose expression regulatory
mechanisms. However, NGS-derived stud-
ies have often been conducted using single
fragments/biopsies of primary tumors, and
therefore fail to reflect the global tumor
heterogeneity, dynamics, and drug sensitiv-
ities, likely to change during tumor evolu-
tion and treatment. For these reasons, there
is the need to develop strategies that may
accurately capture the entire landscape and
allow following clonal evolution of tumor
populations.
Scientific evidence supports that most
types of cells secrete small vesicles (exo-
somes and microvesicles) into the extra-
cellular milieu (5), and that tumor cells in
particular produce at least threefold more
of these small vesicles than normal cells
(6–8). These so-called extracellular vesicles
(EVs) are emerging mediators of intercel-
lular communication and orchestrators of
health and disease, and contain a reper-
toire of genetic information (incorporated
in DNA, RNA, microRNAs, and proteins),
which may be a fingerprint of the releas-
ing cell type (9, 10). EVs can be easily
detected in biological fluids such as plasma,
serum, ascites, or urine, and provide excel-
lent minimally invasive biomarker candi-
dates to monitor cancer patients’ progres-
sion, prognosis, and treatment efficacy (10,
11). In fact, tumor-derived exosomes in
patients’ bloodstream were shown to con-
tain fractions of tumor genome, transcrip-
tome, and proteome such as KRAS, TP53
mutations in pancreatic and colon can-
cer (12); mutant/variant EGFRvIII mRNAs
in glioblastoma (13); microRNAs in ovar-
ian cancer (14); MET in melanoma (15);
and HER2 in breast cancer (16). Further,
double-stranded DNA (exoDNA) repre-
senting the entire genome and reflecting
the mutational status of parental tumor
cells [e.g., BRAF(V600E) and EGFR exon
19 deletion — del19], was found in EVs
from melanoma and non-small cell lung
cancer cell lines (17). From a clinical
perspective, molecules enclosed in EVs
harbor potential usefulness as circulating
biomarkers with impact in early detec-
tion and during cancer progression. Apart
from carrying specific molecular signatures
and disease effectors, EVs also contribute
to horizontal cellular transformation and
phenotypic reprograming, both locally and
systemically (8, 10, 15, 18).
The identification of specific EV fea-
tures has allowed developing isolation and
characterization methodologies that have
been used in numerous studies (19–21).
Most of these have been focused on the
characterization of the cargo of EVs in dif-
ferent types of cancer, using either condi-
tioned media of cancer cell lines, or unique
samples from cancer patients’ body flu-
ids. Cancer cell line studies have provided
markers of EVs for different types of can-
cers, however, lack the representativeness of
cancer as a heterogeneous cell population.
Unique samples from cancer patients’ body
fluids have highlighted potential markers
for cancer diagnosis and prognosis in cross-
sectional studies, although fail to deliver
useful information to monitor tumor het-
erogeneity and dynamics,and to allow ther-
apy response and recurrence assessment.
Longitudinal studies of cancer patients,
from whom samples are repeatedly col-
lected along diagnosis, treatment, and
follow-up, have been rarely reported,
and may be the most adequate tools
to address the abovementioned limita-
tions. One possible longitudinal approach
should enclose the molecular profiling
of the following patient-derived samples:
(1) biopsy/surgical tumor specimens; (2)
body fluid-derived EVs collected prior/at
surgery; (3) body fluid-derived EVs col-
lected immediately after surgery; (4) body
fluid-derived EVs collected along therapy
cycles, and; (5) body fluid-derived EVs col-
lected after disease remission (if possible).
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The comparative analysis of data derived
from each of these datasets will shed light
into cancer-specific signatures that become
represented in tumor-derived EVs (bio-
marker candidates), and that should be
used to monitor tumor evolution, dynam-
ics, and therapy response, as well as pre-
dict disease recurrence. This type of stud-
ies raises the need for close collaborations
between clinical and basic research teams,
to set-up effective study designs and eth-
ically approved protocols, to allow collec-
tion of multiple samples and clinically rel-
evant information from each individual
patient. The power of this approach is the
possibility of providing information use-
ful for the design of precision-medicine
approaches, with impact in clinical
practice.
In summary, in this article, we dis-
cuss the impact of performing longi-
tudinal studies through the analysis of
EVs from cancer patients, to improve
our understanding of tumor heterogene-
ity/evolution, and to identify minimally
invasive markers, potentially useful for dis-
ease management of cancer patients. We
further present a workflow that may be
useful to consider when designing longi-
tudinal studies involving cancer patients.
Despite lengthy and labor-intensive, such
studies will certainly provide answers for
currently unsolved questions in cancer
research.
At this point, it is clear that EVs have
a tremendous potential to be used as a
“liquid biopsy” for cancer patients, which
would be less invasive compared to surgery
and may provide diagnostic information,
aid in therapeutic decisions, and monitor-
ing of disease over time, on a personalized
basis.
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